different pathogens have been associated with the development of subsequent joint inflammation", but material from such joints has invariably proved to be sterile. As a result, the concept of 'reactive' arthritis has emerged. In the UK, the commonest cause of reactive arthritis appears to be sexually acquired urethral infection by Chlamydia traehomatiss although other microorganisms may also be involved. The mechanistic link between the precipitating infection and synovial inflammation remains the subject of speculation, but there is preliminary evidence that in sexually acquired reactive arthritis, chlamydial antigens are present in inflamed synovium'', Similar evidence of dissemination of bacterial antigens has been found in reactive arthritis associated with yersinioais-", Urethritis, however, occurs in many cases of reactive arthritis in which sexually transmitted infection has been excluded and is commonly present in patients in whom the arthritis has been triggered by gut infection. It is possible that, in such cases, an urethral pathogen has escaped detection. Alternatively, the urethritis may, like the synovitis, be truly 'reactive'. The case report by Maxwell suggests that the latter explanation is correct. The urachal remnant is closely related embryologically to the urethra and has a similar uroepithelium but in this particular case the urachal sinus had no patent connection with the urogenital tract. In the absence of any extraordinary sexual practices, direct infection of the urachus would seem unlikely and the urachal tissue would not be directly accessible to any urethral microorganisms. The urachal inflammation would, therefore, seem to arise as a 'reaction' to the same factors that caused the relapse of the reactive arthritis. Whether or not there was re-infection of the urethra in this episode is unclear.
It would be of great interest to examine the urachal specimen further by using immunohistochemical techniques to look for bacterial antigens. It may be that such antigenic material is an important factor in the pathogenesis of the synovitis, urethritis and inflammation of the urachus. R A HUGHES Yersinia specificimmune complexesin the synovial fluid of patients with yersinia triggered reactive arthritis. Ann Rheum Dis 1987; 46:510-14 Back pain at Greenwich Sir, Blower's article (April 1988 JRSM, p 203) is beautifully written and researched. However, I believe, it is misleading on the subject of neurological loss in sciatica.
Department of Rheumatology
I agree with his point that a patient with a definite single root weakness has an organic complaint (a prolapsed disc), however highly strung they may be. He then says that such patients are excellent candidates for surgery, with the implication that they should be referred for surgery.
James Cyriax! noted that a huge majority of patients with a nerve root palsy did very well without surgery. My own experience bears this out and I have also found that those patients with the most obvious definite neurological signs lose their pain the soonest. (Those with a suggestion of nerve root damage which never progresses to the full-blown picture are more difficult to manage without an operation.) Most orthopaedic surgeons on this side of the Atlantic prefer to operate on discs only when there is no alternative. Thus, I think it is important to recognize that the vast majority of patients with a nerve root palsy (due to a prolapsed disc) will do very well with an operation, but even better without one. N A WATSON London Reference 1 Cyriax JH. Textbook oforthopaedic medicinevol1; London:
Bailliere Tindall, 1982 Hyperbaric oxygen in multiple sclerosis
Sir, Dr Bates reviewed the results of this controversial treatment (September 1986 JRSM, p 535) without waiting for the final results of his own study'. This has now provided further evidence that additional oxygen may benefit multiple sclerosis patients, although the authors of this study continue to deny that it will be of value in the management of the disease. The preliminary communication from the Newcastle study2 reported improvements in 16 out of 60 patients in the oxygen group, compared to 4 out of 57 in the controls (P< 0.01), with 12 of these patients reporting improved bladder and bowel function, compared to 3 of the controls (P< 0.03).Clearly disappointed by their failure to reproduce the highly significant results of Fischer et aP, and without waiting for their trial to be completed, they concluded that, 'hyperbaric oxygen is unlikely to have a role in the management of a patient with multiple sclerosis.' However, their final results! show that the benefit in bladder bowel function in the oxygen group, assessed on the Kurtzke scale, was actually sustained for 6 months without additional treatment. This confirms improvement shown in 4 other double-blind studies 3 -e, two with objective evidence from detailed cystometric measurements 5 • e. It must be remembered that all of the trials to date have used chronically disabled patients. Dr Bates obviously must accept that bladder function is important in the management of multiple sclerosis and he has already admitted that any treatment found to be of value should be used in patients with less advanced disease", Multiple sclerosis patients with early bladder and bowel dysfunction must now be offered hyperbaric oxygen therapy.
The final report by Barnes et al. 1 also records a significant reduction in the rate of cerebellar deterioration in the oxygen group compared to the controls at one year (P<0.05). They state that, 'if this finding can be confirmed, then it may be of benefit to patients as there is no consistently successful treatment for cerebellar dysfunction.'
Their study actually provides confirmation of benefit found in the trial by Fischer et at. 3 A new double-blind, controlled study of one year of hyperbaric oxygen therapy" has also reported a positive effect on cerebellar function and from visual and brain stem evoked potential studies.
Unfortunately, it seems that scientific proof alone will not be sufficient to convince the opponents of this treatment, but Dr Bates, on his own admission, must revise his position. both interesting and instructive. I have the feeling that Dr Young is living a long way from the cutting edge of modern management budgeting. While our DHA Directorate is ankle deep in computers costing thousands of pounds, I have only just managed to scrounge a secondhand computer surplus to the requirements of our finance department. This, at least, will allow us to put some of our more routine waiting lists onto disc, but it has been largely a matter of luck. The clinical staff have not been encouraged to use computers in their work, and the computers themselves have always been taken from the medical equipment budget. Since it has always been a matter of balancing computers against hard equipment such as replacement monitors, there has been no possibility of supplying ourselves with these aids for diagnosis 
Simplifying infusion chemotherapy
Sir, The object of breast cancer chemotherapy is to make as many patients as possible as well as possible for as long as possible. The preliminary communication by Ebbs et al: (January 1988 JRSM, p 13) raises worrying therapeutic and ethical questions. The use of single drugs in patients with advanced breast cancer is questionable because combination chemotherapy produces higher response rates and a greater chance of significant prolongation of good quality life 1 ,2,3 Having reduced their patients' prognoses by choosing to use single drugs, the King's Group refuse to use what they admit is the most effective single agent, i.e. adriamycin which, they say, is 'extremely toxic'. This statement is scientifically meaningless. The side effects of any drug are not only a function of the chemical properties of the compound as such but also of the way in which it is given. It is illogical to make sweeping generalizations about the side effects of drugs without stating how they were given and what steps were taken to minimize such effects. For example, the side effects of most combination cancer chemotherapy programmes, including those with adriamycin, can be significantly reduced by admitting the patients to hospital, giving them high doses of combined antiemetics as a premedication and administering the drugs in full doses over 24 h instead of over several days. Approximately 80% of patients treated in this way will have no vomiting or diarrhoea, only rarely experience nausea, and lead a virtually normal life between treatment cycles. Apart from temporary alopecia there is not a single side effect of adriamycin which cannot be avoided by giving the drug by this method and observing a few simple and well known precautions. The validity of this approach has been extensively tested over the last 15 years 4 -6 and confirmed by several different groups7,8
This raises the question of whether these patients are being informed that they are not being given the currently best available treatment. If they are not so informed, this poses a serious ethical dilemma: either the King's Group are unaware of facts which it is their duty to know or they are giving suboptimal treatment to uninformed patients. Either way, in my opinion, the study is unethical. Failure to realize that anticancer drugs can now be given much more safely and with far fewer side effects than in the past is wrong for two reasons: (1), many patients receiving chemotherapy are sutTering from side effects which could largely be prevented, and (2), the constant emphasis on only the negative aspects of the drug treatment of breast cancer means that many patients with advanced disease are being deprived of the benefits of optimum chemotherapy as are those with 'high risk' tumours at the time of diagnosis, many of whom are being given adjuvant tamoxifen alone instead of tamoxifen plus combination chemotherapy. This situation will never improve unless we base our
